2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms

AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with fluoropyrimidines.

Read the full article here

Source: www.aacr.org

Categories: Oncologists1, General Medicine News

Tweets with this article

FDA Oncology

FDA Oncology and @AACR are jointly holding a workshop to discuss DPD deficiency testing, the current landscape and future directions. Hope to see many of you there on January 16, 2025 – register for in-person or virtual attendance. https://t.co/sR2xT0QGI0

Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer

Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast…

OncLive.com January 10, 2025

Cardio Onc year in review

JACC: CardioOncology, 2024, Year-in-review, most viewed papers, best of 2024

Oncology Advance January 10, 2025

FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC

The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

OncLive.com January 10, 2025

Impact of Non-ABL1 Mutations on Outcomes in Chronic Myeloid Leukemia

Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.

Targeted Oncology January 10, 2025

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

OncLive.com January 10, 2025

AUA 2024: Disrupting the Field of Urology

Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.